Table 5 Laboratory data of both studied groups
From: Genetic, clinical, and biochemical aspects of patients with Alzheimer disease
|  | AD group (n = 40) | Control group (n = 40) | P value |
|---|---|---|---|
Cholesterol (mg/dl) | 203.45 ± 41.19 | 136.20 ± 27.82 |  < 0.001 |
 Risk level |  |  |  < 0.001 |
 No | 19 (47.5%) | 40 (100%) |  |
 Borderline | 16 (40%) | 0 |  |
 High risk | 5 (12.5%) | 0 |  |
Triglycerides (mg/dl) | 163.17 ± 80.15 | 101.25 ± 26.10 |  < 0.001 |
 Risk level |  |  |  < 0.001 |
 No | 23 (57.5%) | 36 (90%) |  |
 Borderline | 4 (10%) | 4 (10%) |  |
 High risk | 13 (32.5%) | 0 |  |
HDL (mg/dl) | 47.77 ± 14.60 | 42.05 ± 4.74 | 0.02 |
 Risk level |  |  | 0.03 |
 No | 5 (12.5%) | 0 |  |
 Borderline | 8 (20%) | 4 (10%) |  |
 High risk | 27 (67.5%) | 36 (90%) |  |
Non-HDL (mg/dl) | 151.57 ± 37.45 | 94.15 ± 27.45 |  < 0.001 |
 Risk level |  |  |  < 0.001 |
 No | 9 (22.5%) | 35 (87.5%) |  |
 Near optimal | 19 (47.5%) | 5 (12.5%) |  |
 Borderline | 7 (17.5%) | 0 |  |
 High | 3 (7.5%) | 0 |  |
 Very high | 2 (5%) | 0 |  |
LDL (mg/dl) | 122.36 ± 33.83 | 73.76 ± 25.86 |  < 0.001 |
 Risk level |  |  |  < 0.001 |
 No | 9 (22.5%) | 30 (75%) |  |
 Near optimal | 15 (37.5%) | 10 (25%) |  |
 Borderline | 13 (32.5%) | 0 |  |
 High | 1 (2.5%) | 0 |  |
 Very high | 2 (5%) | 0 |  |
VLDL (mg/dl) | 32.37 ± 16.02 | 22.94 ± 6.57 |  < 0.001 |
 Risk level |  |  |  < 0.001 |
 No | 26 (65%) | 37 (92.5%) |  |
 High risk | 14 (35%) | 3 (7.5%) |  |
Cholesterol/HDL ratio | 4.49 ± 1.27 | 3.31 ± 0.77 |  < 0.001 |
 Risk level |  |  |  < 0.001 |
 Low risk | 19 (47.5%) | 36 (90%) |  |
 Average risk | 18 (45%) | 4 (10%) |  |
 Moderate risk | 3 (7.5%) | 0 |  |
Thyroid function | |||
 T3 | 131.61 ± 52.58 | 129.47 ± 27.62 | 0.821 |
 T4 | 9.35 ± 5.43 | 7.83 ± 1.54 | 0.09 |
 TSH | 2.67 ± 2.16 | 1.86 ± 0.81 | 0.06 |